Reflecting on the molecular pathology of TDP-43, this review provides a critical overview on biofluid studies and future directions to develop a TDP-43-based clinical biomarker for ALS and FTLD. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.